Futura Medical PLC
LSE:FUM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Futura Medical PLC
Cash from Financing Activities
Futura Medical PLC
Cash from Financing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Futura Medical PLC
LSE:FUM
|
Cash from Financing Activities
£181.9k
|
CAGR 3-Years
57%
|
CAGR 5-Years
-43%
|
CAGR 10-Years
25%
|
|
|
GlaxoSmithKline PLC
LSE:GSK
|
Cash from Financing Activities
-£3.7B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
18%
|
CAGR 10-Years
6%
|
|
|
AstraZeneca PLC
LSE:AZN
|
Cash from Financing Activities
-$7.5B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
N/A
|
|
|
Hikma Pharmaceuticals PLC
LSE:HIK
|
Cash from Financing Activities
-$25m
|
CAGR 3-Years
24%
|
CAGR 5-Years
39%
|
CAGR 10-Years
N/A
|
|
|
Allergy Therapeutics PLC
LSE:AGY
|
Cash from Financing Activities
£25.1m
|
CAGR 3-Years
92%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-2%
|
|
|
A
|
Alliance Pharma PLC
LSE:APH
|
Cash from Financing Activities
-£30.9m
|
CAGR 3-Years
3%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-19%
|
|
Futura Medical PLC
Glance View
Futura Medical Plc is a pharmaceutical group that develops products for both the prescription and consumer healthcare markets. The company is headquartered in Guildford, Surrey and currently employs 13 full-time employees. The company went IPO on 2006-07-10. The firm is focused on developing a portfolio of products based on its transdermal DermaSys technology. Its patented transdermal DermaSys technology provides rapid and targeted local delivery of medical treatments via the skin. The firm is engaged in developing a portfolio of products for therapeutic areas, such as sexual health, including erectile dysfunction, and pain relief. The firm's products include MED3000 and TPR100. The firm's lead product, MED3000, is a topical gel formulation treatment for erectile dysfunction (ED) through an evaporative mode of action. The firm has conducted a Phase III study using MED3000 in ED. TPR100 is a topical non-steroidal anti-inflammatory for the pain and inflammation associated with sprains, strains and bruises and soft tissue rheumatism.
See Also
What is Futura Medical PLC's Cash from Financing Activities?
Cash from Financing Activities
181.9k
GBP
Based on the financial report for Jun 30, 2025, Futura Medical PLC's Cash from Financing Activities amounts to 181.9k GBP.
What is Futura Medical PLC's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 10Y
25%
Over the last year, the Cash from Financing Activities growth was 11%. The average annual Cash from Financing Activities growth rates for Futura Medical PLC have been 57% over the past three years , -43% over the past five years , and 25% over the past ten years .
